Complex decision-making simplified by sophisticated data

More than two million adverse drug events (ADEs) occur annually, causing 124,00 deaths each year in the United States, and 60% of these deaths are preventable1. Clinical screening seeks to reduce the number of ADEs, occurring across the continuum of care—from e-prescribing, to dispensing, to claims management. A crucial part of any successful clinical screening approach is ensuring that many complex factors are considered—dosing, adverse effects, allergies, and more—for every single medication decision. Healthcare professionals need to make these complex decisions quickly, at scale. When you need to make a decision quickly, we have the answers you need to feel confident about your choice.

Give your healthcare professionals the confidence they need when making medication decisions

Medi-Span provides workflow-integrated data solutions that take into account available patient information to help healthcare professionals make safe, efficient medication decisions. Our evidence-based drug data is designed to help address complex, patient-specific clinical scenarios to support you in making safe, appropriate medication decisions for the patient. Medi-Span data supports modern pharmacy operations, from the development of e-prescribing and CPOE modules, to the support of vital patient safety initiatives, surveillance, and therapy management.

Medi-Span supports your clinical screening goals by providing:

  • Patient safety content especially designed to help healthcare professionals enhance patient well-being
  • Centralized drug utilization review (DUR) to streamline medication review
  • Mapping solutions necessary for e-prescribing and other interoperability needs
  • Clinical content supporting healthcare systems; retail, mail order, and specialty pharmacies; ambulatory/acute care; long-term care EHRs; and more
Learn More About Our Approach to Clinical Screening
Medi-Span, in my view, beats everyone else. It helps you find twice as many drug errors—errors that would lead to readmission—in half the amount of time.
Keith Streckenbach

1 Source: U.S. Food and Drug Administration (FDA)